The Peptide That Out-Performed Ozempic in Research
A 90-day lab study compared four groups of research specimens. One group's results were nearly 13× better than the control. Here's what happened — and why.
First: The Control Group Got Almost No Results
We started by watching a group of research specimens with no compounds at all — just the same diet and conditions as everyone else.
After 90 days, fat mass dropped just 2.1%. That's basically nothing.
This is the starting point. Every other result gets compared to this group.
Ozempic Flips One Switch. This Compound Flips Three.
Think of your metabolism like a machine with three ON/OFF switches. Ozempic flips one. Mounjaro flips two. Retatrutide flips all three — including one that makes the body burn stored fat directly, even at rest.
(Ozempic / Wegovy)
(Mounjaro)
Triple Agonist · Research
Phase 2 Clinical Trial
1 switch
2 switches
3 switches
Phase 2 Clinical Trial
There's a Fourth Signal Nobody Talks About
Your body has a natural "I'm full" signal called amylin. It fires after eating to tell the brain to stop. In specimens with metabolic problems, this signal gets weak — the brain stops hearing it. That's why hunger keeps coming back even after eating.
Ozempic doesn't touch this signal at all. That's why some specimens still act hungry even while on it.
When both compounds were used together in our observation, hunger behavior dropped to just 6% of what it was at the start.
The 90-Day Numbers: All Four Groups, Side by Side
| Group | Pathways Hit | Fat Mass Δ | Hunger Drop | Muscle |
|---|---|---|---|---|
| Control | None | −2.1% | 11% | No change |
| Cagrilintide only | Amylin | −9.4% | 67% | Kept |
| Retatrutide only | 3 receptors | −19.7% | 81% | Kept |
| Full Stack | All 4 pathways | −24.1% | 94% | Gained |
Lab Log: What We Watched Happen to Our Research Mouse
Numbers are one thing. Here's what we actually saw — week by week — with our primary research specimen (a diet-induced obese mouse model, labeled M-01).
Why the Full Stack Beat Everything Else
Using both compounds together wasn't just "a little better" — it was the only way to hit all four broken pathways at once. Retatrutide handles 3 receptors. Cagrilintide handles the amylin signal. They don't compete. They stack.
Published clinical trials on combined amylin + GLP-1 compounds (CagriSema) confirmed this pattern — better results together than either alone.
Access the Research.
Outside the System.
Retatrutide, Cagrilintide, and KLOW 80 — pharmaceutical-grade, third-party verified. No insurance. No $1,300/month.
View Research Compounds at Trutide →All products ship with third-party Certificate of Analysis · trutide.net